TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02811562

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: manikin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manikin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fiberoptic bronchoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fiberoptic bronchoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pentax-airwayscope
Study: NCT01247974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorMatrix ECM for Pericardial Closure
Description: Circumferential closure of the pericardium following CABG surgery using the CorMatrix ECM for Pericardial Closure
Study: NCT04359420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BC-Predict
Description: BC-Predict is an automated system for offering an assessment of breast cancer risk to women when they receive their NHS Breast Screening Programme invitation, and generating letters to feedback this risk to women and relevant healthcare professionals. Women at higher risk are offered chemoprevention drugs and additional mammography

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NHS Breast Screening Programme
Description: usual care from NHS Breast Screening Programme, consisting of mammography every three years for most women.
Study: NCT02594137

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Without watertight duraplasty
Description: After standard craniectomy and dural opening, provided there is no brain contusions or hematomas requiring surgical evacuation, no watertight duraplasty is performed. The dura is left opened and the brain parenchyma is covered with Surgicel. Usual closure is then performed.
Study: NCT02105597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: The intervention in this study is a mobile application which will be downloaded into the participant's smartphone.
Study: NCT00549120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 40 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 40 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 40 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Metered dose inhaler (600 μg)
Study: NCT03517644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DP
Description: Participants are informed that they are about to receive an effective analgesic cream. They are instructed to apply the cream using a cotton pad.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OLP Hope
Description: Participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. Therefore, participants are supposed to evaluate the subjective probability for a positive effect of the cream as rather low. However, using verbal instructions, the investigator aims to induce hope among the participants that the cream could have a positive effect for them because this placebo cream did have a positive among some former participants who were similar to the current participant. The emphasis of this similarity (regarding age and sex) aims to induce a feeling of connectedness to previous participants who reported positive effects of the placebo cream.
Study: NCT00549120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Metered dose inhaler (600 μg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Metered dose inhaler (600 μg)
Study: NCT03517644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OLP Expectation
Description: Participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, participants are told that placebos have been shown to contribute substantially to clinical outcomes such as pain intensity/unpleasantness. This positive effect of placebos is reasoned by explaining learning mechanisms such as classical conditioning. We anticipated that after hearing this instruction, participants would consider it to be likely that the placebo has a positive effect for them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo cream
Description: The participants receive an inert placebo cream (standard basic cream with oil of thyme produced by a local pharmacy).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo cream
Description: The participants receive an inert placebo cream (standard basic cream with oil of thyme produced by a local pharmacy).
Study: NCT01400945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGSPT201 Tab contains S-pantoprazole
Description: comparison of Pantoloc Tab 40mg
Study: NCT03517644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo cream
Description: The participants receive an inert placebo cream (standard basic cream with oil of thyme produced by a local pharmacy).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat pain
Description: Participant receive heat pain stimuli using the suprathreshold method of the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat pain
Description: Participant receive heat pain stimuli using the suprathreshold method of the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat pain
Description: Participant receive heat pain stimuli using the suprathreshold method of the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
Study: NCT00549120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Metered dose inhaler (600 μg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium
Description: Metered dose inhaler (40 μg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium
Description: Metered dose inhaler (40 μg)
Study: NCT03517644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat pain
Description: Participant receive heat pain stimuli using the suprathreshold method of the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
Study: NCT01882959

Intervention type: OTHER
Intervention: Radiofrequncy Denervation
Study: NCT00549120

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for propranolol tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for propranolol tablets
Study: NCT02618473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-seloken
Description: regarding the guidelines patients receive seloken before the cardiac CT scan to lower the heart rate during the scan. The intervention in this study is to avoid the medication with seloken before the scan, and to investigate if the use of a new motion correction scan algorithm can compensate for the absence of the seloken.
Study: NCT00549120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for propranolol tablets
Study: NCT06541236

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar Ridge Preservation After Tooth Extraction Using Autologous Dentin Matrix
Description: Incorporation of various bone grafting materials for alveolar ridge preservation
Study: NCT01340703

Intervention type: PROCEDURE
Group type: OTHER
Intervention: vitrectomy without laser or gas tamponade
Description: vitrectomy without laser or gas tamponade
Study: NCT02379676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 90mg twice daily for 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75mg once daily for 30 days
Study: NCT01365676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAMALINE® + HIPERICIN®
Description: GAMALINE® 900mg + HIPERICIN 300mg T0 = 2 soft caps of each / day (1st month) T1-T6 = 1 soft caps of each / day (2nd - 6th month)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAMALINE® + HIPERICIN®
Description: GAMALINE® 900mg + HIPERICIN 300mg T0 = 2 soft caps of each / day (1st month) T1-T6 = 1 soft caps of each / day (2nd - 6th month)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GAMALINE®
Description: GAMALINE® 900mg T0= 2 soft caps / day (1st month) T1-T6 = 1 soft caps / day (2nd - 6th month)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GAMALINE®
Description: GAMALINE® 900mg T0= 2 soft caps / day (1st month) T1-T6 = 1 soft caps / day (2nd - 6th month)
Study: NCT02406365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic imaging aid for one-visit management of cervical lesions
Study: NCT03668925

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement
Description: magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement
Description: magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement
Study: NCT03023098

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PTA
Description: After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a conventional balloon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon
Description: After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a drug-eluting balloon
Study: NCT00850837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acidform Lubricant
Description: 5 g application of acid buffered gel (pH = 3.5)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC gel
Description: 5 g application of hydroxyethylcellulose gel
Study: NCT04017026

Intervention type: DEVICE
Intervention: Implantation
Description: Implantation of 6 mm short implants
Study: NCT03424694

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy as monotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy as monotherapy
Study: NCT01880541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypnosedation
Description: hypnosedation

Intervention type: OTHER
Group type: OTHER
Intervention: general anesthésia
Description: general anesthesia
Study: NCT04144231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT-I
Description: Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GCBT-I
Description: Cognitive Behavioral Group Therapy for Insomnia (GCBT-I)
Study: NCT03087929

Intervention type: OTHER
Intervention: Follow up
Study: NCT03077594

Intervention type: DEVICE
Intervention: Mucosal Impedance
Description: Aim 1: Mucosal impedance will be measured by an endoscopic probe 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Mucosal impedance will be measured 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.

Intervention type: DEVICE
Intervention: Mucosal Impedance
Description: Aim 1: Mucosal impedance will be measured by an endoscopic probe 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Mucosal impedance will be measured 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.

Intervention type: OTHER
Intervention: Research Biopsies
Description: Aim 1: Research biopsies will be obtained at 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction, and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Aim 2: Research biopsies will be taken 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.

Intervention type: OTHER
Intervention: Research Biopsies
Description: Aim 1: Research biopsies will be obtained at 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction, and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Aim 2: Research biopsies will be taken 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.

Intervention type: DEVICE
Intervention: Volumetric Laser Endomicroscopy
Description: Aim 2: Volumetric laser endomicroscopy will be done and marked at 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
Study: NCT01097850

Intervention type: DRUG
Group type: OTHER
Intervention: henna paste
Description: Henna paste will be applied to either the left hand/foot or right hand/foot, along with CeraVe moisturizer to both hands/feet

Intervention type: DRUG
Group type: OTHER
Intervention: henna paste
Description: Henna paste will be applied to either the left hand/foot or right hand/foot, along with CeraVe moisturizer to both hands/feet
Study: NCT04779411

Intervention type: OTHER
Intervention: Weekly Food Frequency Questionnaire
Description: A purpose designed 91-item questionnaire to measure frequency of consumption of a selection of L/Z containing foods over the prior 7 days.

Intervention type: OTHER
Intervention: Monthly Food Frequency Questionnaire
Description: A purpose designed 95-item questionnaire completed at visit 1 to measure frequency of consumption of a selection of L/Z containing foods over the prior month.
Study: NCT02428036

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBI-1401(HF10)
Description: Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10\^6 TCID50/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBI-1401(HF10)
Description: Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10\^7 TCID50/mL.
Study: NCT01184014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPH insulin plus Complete Insulin Orders
Description: NPH dosed per study-specific algorithm which incorporates total daily dosage of steroid to determine NPH dose. Complete insulin orders include background, meal-time and correction factor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Complete Insulin Orders
Description: 3-part insulin which includes background, meal-time and correction factor
Study: NCT02446808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative nerve monitoring
Description: Intraoperative nerve monitoring (electromyography) is used to identify the location of somatic pelvic nerves critical to urinary continence control and erectile function in real time during robotic-assisted laparoscopic prostatectomy surgery
Study: NCT00148343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Odstock Dropped-Foot Stimulator (ODFS)
Description: Device implementation \& use for \~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The ODFS then will be returned to the investigators.
Study: NCT00043368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3512676
Description: PF-3512676 IV at doses: 0.01mg/kg, 0.16mg/kg and 0.32mg/kg PF-3512676 Injection given by subcutaneous injection at doses: 0.04mg/kg, 0.16mg/kg, 0.20mg/kg, 0.28mg/kg, 0.32mg/kg, 6mg, 10mg, 40mg.
Study: NCT00148343

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Standard of Care
Description: Conventional standard of care (which may include implementation \& use of a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) for \~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The AFO, if implemented, may continue to be used afterwards since it is an element of the standard of care for this patient population.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Physical Therapy Treatment
Description: Traditional physical therapy treatment for 12 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy Treatment
Description: Traditional physical therapy treatment for 12 weeks.
Study: NCT03455283

Intervention type: DRUG
Intervention: Clariscan
Description: Clariscan 0.5 mmol/ml solution for injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.

Intervention type: OTHER
Intervention: Gadolinium-Based Contrast Agents
Description: All GBCAs will be selected by the sites and recorded as by the brand names.
Study: NCT03663114

Intervention type: DRUG
Intervention: Lenvatinib
Description: Lenvatinib capsule
Study: NCT02773589

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peroral endoscopic myotomy
Description: Peroral endoscopic myotomy
Study: NCT00745017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy
Description: All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Description: Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
Study: NCT03925636

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Specific Carbohydrate Diet
Description: The diet removes all grains such as wheat, barley, corn, rice, and most dairy products (except yogurt fermented for 24 hours and cheese aged for grater than 30 days). The diet mainly consists of meat, fruits, vegetables, nuts, oils, and honey.
Study: NCT02612012

Intervention type: RADIATION
Intervention: axillary radiotherapy
Description: Whole breast irradiation and axillary level I-II areas radiotherapy. The prescription dose is 50Gy in 25 fractions in 5 weeks. Tumor bed boost is necessary with 10Gy in 5 fractions in one week.
Study: NCT02317458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: One active arm with standard of car and treatment with C3BR-CQR-1 using intramyocardial injection

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: One arm with standard of care undergoing a sham procedure
Study: NCT00462384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy Polyethylene Glycol-epoetin Beta
Description: Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.
Study: NCT00919282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine, folinic acid, 5-FU
Description: gemcitabine 1g/m² - 30 minutes folinic acid 500mg/m² - 2 hours 5-FU 750mg/m² - over 24hours
Study: NCT02053233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walkbot group
Description: The physiotherapist typed patient's information then Walkbot would adjust itself to this data and the exoskeleton legs lengthen or shorten to the patient. The computer screen would provide information about speed, duration, cadence and distance. The monitor in front of the patient can offer image and feedback during the therapy process for patients.~The whole Walkbot training process was observed by one physiotherapist and should be always ready to adjust the unloading, duration, speed and guidance force of Walkbot according to patients' different situation such as muscle spasticity, gait quality, labor-consuming and observe the changes of patients' state.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
Study: NCT02024334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Study: NCT01230476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab loading dose of 400mg/m2, then weekly dose of 250mg/m2 for 12 doses; Neoadjuvant Cisplatin 75mg/m2 D1, 5FU 1000mg/m2 D2-5, for 2 cycles; Concurrent Cisplatin 30mg/m2 given with radiation 70Gy/35fraction/7weeks.
Study: NCT00059813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: Given SC
Study: NCT04779411

Intervention type: OTHER
Intervention: 24-Hour Diet Recall
Description: the diet recall via the online Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24®) takes approximately 25 minutes to complete, and investigates food and beverages consumed in the prior 24-hours.

Intervention type: OTHER
Intervention: Electronic Device Use Questionnaire
Description: 1. The EDUQ: A 22-item questionnaire that takes 20 minutes to complete, and measures participant demographic information (weight, height, age, highest level of education, occupational status, post-code and country of residence), usual daily ED use from present up to 20 years ago, occupational influence to use, and differences to ED use between a weekend and weekday.

Intervention type: OTHER
Intervention: 24-Hour Electronic Device Use Diary
Description: Participants asked to record their electronic device use in hours and minutes over 24 hours.